ClinicalTrials.gg
TerminatedNCT02520284Updated Apr 10, 2019Results posted

Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis

A Phase 2/3 interventional study of Andecaliximab and Placebo in Ulcerative Colitis, sponsored by Gilead Sciences. Terminated at 88 sites in 23 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-04-10.

Sponsored by Gilead Sciences · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 615 studies in Colitis, Ulcerative with a site in United States — 116 open to participants now, 167 under way, 34 of them phase 3. Colitis, Ulcerative · United States.

Enrollment
163rd of 499
165 · median 76
Started
2015
with 32 others
Phase 2/3
16 of 615
1 open now
Registered
228th of 615
by date

Among the 615 studies in Colitis, Ulcerative with a site in United States, this one is the 163rd largest by enrollment of the 499 interventional ones that give a count, is one of 33 that started in 2015, is one of 16 in phase 2/3, and was the 228th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

116 of the 615 studies in Colitis, Ulcerative with a site in United States are open now. Recruiting first, the newest first:

111 more — sign in →

All 116 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 615 studies in Colitis, Ulcerative with a site in United States, or all of them as a file.
02

Study summary

The primary objectives of this study are as follows: 1) To evaluate the efficacy of andecaliximab to induce endoscopy, rectal bleeding, and stool frequency (EBS) clinical remission at Week 8 (Cohort 1); 2) To evaluate the efficacy of andecaliximab to maintain EBS clinical remission at Week 52 (Cohort 2); and 3) To evaluate the safety and tolerability of andecaliximab. The study will consist of 3 parts: Induction Phase (Cohort 1), Maintenance Phase (Cohort 2), and an optional Extended Treatment Phase.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Ulcerative Colitis (UC) confirmed on endoscopy
  • Moderately to severely active UC (Mayo Score 6-12)
  • May be receiving oral 5-aminosalicylate (ASA), oral , azathioprine, 6-mercaptopurine (MP), or methotrexate
  • Treatment failure with at least one of the following agents received: corticosteroids, immunomodulators, tumor necrosis factor-alpha (TNFα) antagonists, vedolizumab

Key Exclusion Criteria:

  • Diagnose of Crohn's disease or indeterminate colitis
  • Pregnant or lactating females
  • Any chronic medical condition (including, but not limited to cardiac or pulmonary disease, alcohol or drug abuse)
  • Exhibit severe UC / active infection
  • History of in the last 5 years

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
165 participants (actual)

Study arms

  • Experimental
    Andecaliximab Every 2 Weeks

    Participants will receive andecaliximab 150 mg administered via subcutaneous (SC) injection alternating with matching placebo weekly for a total of 4 doses of andecaliximab. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.

    Biological: Andecaliximab · Biological: Placebo

  • Experimental
    Andecaliximab Weekly

    Participants will receive andecaliximab 150 mg administered via SC injection once weekly for a total of 8 doses. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.

    Biological: Andecaliximab

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to andecaliximab administered via SC injection once weekly for a total of 8 doses. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.

    Biological: Andecaliximab · Biological: Placebo

Interventions

  • BiologicalAndecaliximab

    Andecaliximab 150 mg administered via SC injection

    Also known as: GS-5745

  • BiologicalPlacebo

    Placebo matched to andecaliximab administered via SC injection

06

What researchers measure

Primary outcomes

  1. For Cohort 1, Percentage of Participants With EBS Clinical Remission at Week 8

    EBS clinical remission was defined as an endoscopic subscore of 0 or 1 (endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]); rectal bleeding subscore of 0 (rectal bleeding subscore range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes); and at least a 1-point decrease in stool frequency from baseline to achieve a subscore of 0 or 1 (stool frequency subscore range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal).

    Time frame: Week 8

Secondary outcomes

  1. For Cohort 1, Percentage of Participants With MCS Remission at Week 8

    The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and physician's global assessment (PGA). The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. The MCS remission was defined as a MCS of ≤ 2 points and no individual subscore \> 1 point. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating disease worsening.

    Time frame: Week 8

  2. For Cohort 1, Percentage of Participants With MCS Response at Week 8

    The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and PGA. The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating disease worsening. The MCS response was defined as a MCS reduction of ≥ 3 points and at least 30% from baseline, with an accompanying decrease in rectal bleeding subscore of ≥ 1 point or an absolute rectal bleeding subscore of 0 or 1.

    Time frame: Week 8

  3. For Cohort 1, Percentage of Participants With Endoscopic Remission at Week 8

    Endoscopic remission was defined as endoscopic subscore of 0. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).

    Time frame: Week 8

  4. For Cohort 1, Percentage of Participants With Endoscopic Response at Week 8

    Endoscopic response was defined as endoscopic subscore of 0 or 1. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).

    Time frame: Week 8

  5. For Cohort 1, Percentage of Participants With Mucosal Healing as Determined by the Geboes Histologic Scoring System at Week 8

    Mucosal healing was defined as elimination of ulcers/erosion, elimination of crypt destruction, elimination of intraepithelial neutrophils, elimination of lamina propria neutrophils, and reduction in lamina propria chronic inflammatory cells to at most a mild increase. When measured by the Geboes histologic scoring system, it was the selection of the following combined scores of ≤ 3 for Grade 0 (Structural Architectural Change), ≤ 1 for Grade 1 (Chronic Inflammatory Infiltrate), ≤ 3 for Grade 2A (Lamina Propria Eosinophils), and 0 for Grade 2B (Lamina Propria Neutrophils), Grade 3 (Neutrophils in Epithelium), Grade 4 (Crypt Destruction), and Grade 5 (Erosion or Ulceration). Total Geboes histologic score ranged from 0 to 22, with higher scores indicating greater disease severity.

    Time frame: Week 8

  6. For Cohort 1, Percentage of Participants With MCS Remission (Alternative Definition) at Week 8

    The MCS remission (alternative definition) was defined as a rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and PGA subscore (range: 0 to 3 with higher score indicating the severe disease) of 0, and an endoscopic subscore (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]) of 0 or 1 for an overall MCS of ≤ 1. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating disease worsening.

    Time frame: Week 8

07

Results

Posted Apr 10, 2019
Limitations and caveats
Due to early termination of the study, Week 52 data were not available, and therefore prespecified Week 52 analyses could not be conducted.

Participant flow

Participants were enrolled at study sites in South Africa, Europe, North America, and Asia Pacific. The first participant was screened on 15 September 2015. The last study visit occurred on 22 November 2016.

Blinded Induction Phase: Up to Week 8
Participant flow — Blinded Induction Phase: Up to Week 8
MilestoneAndecaliximab Every 2 WeeksAndecaliximab WeeklyPlacebo
Started545655
Completed525253
Not completed242
Withdrew: Adverse event130
Withdrew: Withdrew consent111
Withdrew: Study terminated by sponsor001
Blinded Maintenance Phase: Up to Week 51
Participant flow — Blinded Maintenance Phase: Up to Week 51
MilestoneAndecaliximab Every 2 WeeksAndecaliximab WeeklyPlacebo
Started201618
Completed000
Not completed201618
Withdrew: Study terminated by sponsor171115
Withdrew: Disease worsening223
Withdrew: Adverse event110
Withdrew: Disposition error020
Open-Label MaintenancePhase: Upto Week51
Participant flow — Open-Label MaintenancePhase: Upto Week51
MilestoneAndecaliximab Every 2 WeeksAndecaliximab WeeklyPlacebo
Started323534
Completed000
Not completed323534
Withdrew: Study terminated by sponsor252928
Withdrew: Withdrew consent342
Withdrew: Adverse event213
Withdrew: Investigator's discretion211

Outcome measures

PrimaryFor Cohort 1, Percentage of Participants With EBS Clinical Remission at Week 8

EBS clinical remission was defined as an endoscopic subscore of 0 or 1 (endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]); rectal bleeding subscore of 0 (rectal bleeding subscore range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes); and at least a 1-point decrease in stool frequency from baseline to achieve a subscore of 0 or 1 (stool frequency subscore range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal).

Time frame:
Week 8
Reported as:
Number · percentage of participants
For Cohort 1, Percentage of Participants With EBS Clinical Remission at Week 8
percentage of participantsAndecaliximab Every 2 WeeksAndecaliximab WeeklyPlacebo
For Cohort 1, Percentage of Participants With EBS Clinical Remission at Week 87.4 (2.1 to 17.9)1.8 (0.0 to 9.6)7.3 (2.0 to 17.6)
SecondaryFor Cohort 1, Percentage of Participants With MCS Remission at Week 8

The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and physician's global assessment (PGA). The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. The MCS remission was defined as a MCS of ≤ 2 points and no individual subscore \> 1 point. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating disease worsening.

Time frame:
Week 8
Reported as:
Number · percentage of participants
For Cohort 1, Percentage of Participants With MCS Remission at Week 8
percentage of participantsAndecaliximab Every 2 WeeksAndecaliximab WeeklyPlacebo
For Cohort 1, Percentage of Participants With MCS Remission at Week 87.4 (2.1 to 17.9)1.8 (0.0 to 9.6)7.3 (2.0 to 17.6)
SecondaryFor Cohort 1, Percentage of Participants With MCS Response at Week 8

The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and PGA. The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating disease worsening. The MCS response was defined as a MCS reduction of ≥ 3 points and at least 30% from baseline, with an accompanying decrease in rectal bleeding subscore of ≥ 1 point or an absolute rectal bleeding subscore of 0 or 1.

Time frame:
Week 8
Reported as:
Number · percentage of participants
For Cohort 1, Percentage of Participants With MCS Response at Week 8
percentage of participantsAndecaliximab Every 2 WeeksAndecaliximab WeeklyPlacebo
For Cohort 1, Percentage of Participants With MCS Response at Week 846.3 (32.6 to 60.4)30.4 (18.8 to 44.1)30.9 (19.1 to 44.8)
SecondaryFor Cohort 1, Percentage of Participants With Endoscopic Remission at Week 8

Endoscopic remission was defined as endoscopic subscore of 0. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).

Time frame:
Week 8
Reported as:
Number · percentage of participants
For Cohort 1, Percentage of Participants With Endoscopic Remission at Week 8
percentage of participantsAndecaliximab Every 2 WeeksAndecaliximab WeeklyPlacebo
For Cohort 1, Percentage of Participants With Endoscopic Remission at Week 83.7 (0.5 to 12.7)0.0 (0.0 to 6.4)5.5 (1.1 to 15.1)
SecondaryFor Cohort 1, Percentage of Participants With Endoscopic Response at Week 8

Endoscopic response was defined as endoscopic subscore of 0 or 1. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).

Time frame:
Week 8
Reported as:
Number · percentage of participants
For Cohort 1, Percentage of Participants With Endoscopic Response at Week 8
percentage of participantsAndecaliximab Every 2 WeeksAndecaliximab WeeklyPlacebo
For Cohort 1, Percentage of Participants With Endoscopic Response at Week 818.5 (9.3 to 31.4)7.1 (2.0 to 17.3)14.5 (6.5 to 26.7)
SecondaryFor Cohort 1, Percentage of Participants With Mucosal Healing as Determined by the Geboes Histologic Scoring System at Week 8

Mucosal healing was defined as elimination of ulcers/erosion, elimination of crypt destruction, elimination of intraepithelial neutrophils, elimination of lamina propria neutrophils, and reduction in lamina propria chronic inflammatory cells to at most a mild increase. When measured by the Geboes histologic scoring system, it was the selection of the following combined scores of ≤ 3 for Grade 0 (Structural Architectural Change), ≤ 1 for Grade 1 (Chronic Inflammatory Infiltrate), ≤ 3 for Grade 2A (Lamina Propria Eosinophils), and 0 for Grade 2B (Lamina Propria Neutrophils), Grade 3 (Neutrophils in Epithelium), Grade 4 (Crypt Destruction), and Grade 5 (Erosion or Ulceration). Total Geboes histologic score ranged from 0 to 22, with higher scores indicating greater disease severity.

Time frame:
Week 8
Reported as:
Number · percentage of participants
For Cohort 1, Percentage of Participants With Mucosal Healing as Determined by the Geboes Histologic Scoring System at Week 8
percentage of participantsAndecaliximab Every 2 WeeksAndecaliximab WeeklyPlacebo
For Cohort 1, Percentage of Participants With Mucosal Healing as Determined by the Geboes Histologic Scoring System at Week 818.0 (8.6 to 31.4)13.7 (5.7 to 26.3)22.0 (11.5 to 36.0)
SecondaryFor Cohort 1, Percentage of Participants With MCS Remission (Alternative Definition) at Week 8

The MCS remission (alternative definition) was defined as a rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and PGA subscore (range: 0 to 3 with higher score indicating the severe disease) of 0, and an endoscopic subscore (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]) of 0 or 1 for an overall MCS of ≤ 1. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating disease worsening.

Time frame:
Week 8
Reported as:
Number · percentage of participants
For Cohort 1, Percentage of Participants With MCS Remission (Alternative Definition) at Week 8
percentage of participantsAndecaliximab Every 2 WeeksAndecaliximab WeeklyPlacebo
For Cohort 1, Percentage of Participants With MCS Remission (Alternative Definition) at Week 81.9 (0.0 to 9.9)0.0 (0.0 to 6.4)0.0 (0.0 to 6.5)

Adverse events

Collected over Blinded Induction Phase: First dose of study drug to Week 8; Blinded Maintenance Phase: First dose of study drug up to approximately 39 weeks plus 30 days; Open-Label Maintenance Phase: First dose of open-label andecaliximab up to approximately 41 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Blinded Induction Phase: Andecaliximab Every 2 Weeks0/54 (0%)0/54 (0%)24/54 (44.4%)
Blinded Induction Phase: Andecaliximab Every Weeks0/56 (0%)2/56 (3.6%)31/56 (55.4%)
Blinded Induction Phase: Placebo0/55 (0%)1/55 (1.8%)26/55 (47.3%)
Blinded Maintenance Phase: Andecaliximab Every 2 Weeks0/20 (0%)1/20 (5%)12/20 (60%)
Blinded Maintenance Phase: Andecaliximab Every Week0/16 (0%)2/16 (12.5%)12/16 (75%)
Blinded Maintenance Phase: Placebo0/18 (0%)1/18 (5.6%)13/18 (72.2%)
Open-Label Maintenance Phase From Andecaliximab Every 2 Weeks0/32 (0%)1/32 (3.1%)9/32 (28.1%)
Open-Label Maintenance Phase From Andecaliximab Every Week0/35 (0%)3/35 (8.6%)6/35 (17.1%)
Open-Label Maintenance Phase From Placebo0/34 (0%)2/34 (5.9%)12/34 (35.3%)
Most frequent serious events
Most frequent serious events
EventBlinded Induction Phase: Andecaliximab Every 2 WeeksBlinded Induction Phase: Andecaliximab Every WeeksBlinded Induction Phase: PlaceboBlinded Maintenance Phase: Andecaliximab Every 2 WeeksBlinded Maintenance Phase: Andecaliximab Every WeekBlinded Maintenance Phase: PlaceboOpen-Label Maintenance Phase From Andecaliximab Every 2 WeeksOpen-Label Maintenance Phase From Andecaliximab Every WeekOpen-Label Maintenance Phase From Placebo
Angina pectorisCardiac disorders0/541/560/550/201/160/180/320/350/34
Inguinal herniaGastrointestinal disorders0/540/560/550/201/160/180/320/350/34
Anal abscessInfections and infestations0/540/561/550/200/161/180/320/350/34
Colitis ulcerativeGastrointestinal disorders0/540/560/551/200/160/181/321/351/34
Biliary dilatationHepatobiliary disorders0/540/560/550/200/160/180/320/351/34
Cerebrovascular accidentNervous system disorders0/540/560/550/200/160/180/320/351/34
Cytomegalovirus infectionInfections and infestations0/540/560/550/200/160/180/321/350/34
NephrolithiasisRenal and urinary disorders0/540/560/550/200/160/180/321/350/34
AnaemiaBlood and lymphatic system disorders0/541/560/550/200/160/180/320/350/34
Most frequent other events
Showing 10 of 74
Most frequent other events
EventBlinded Induction Phase: Andecaliximab Every 2 WeeksBlinded Induction Phase: Andecaliximab Every WeeksBlinded Induction Phase: PlaceboBlinded Maintenance Phase: Andecaliximab Every 2 WeeksBlinded Maintenance Phase: Andecaliximab Every WeekBlinded Maintenance Phase: PlaceboOpen-Label Maintenance Phase From Andecaliximab Every 2 WeeksOpen-Label Maintenance Phase From Andecaliximab Every WeekOpen-Label Maintenance Phase From Placebo
Colitis ulcerativeGastrointestinal disorders2/543/561/552/201/164/181/321/353/34
ArthralgiaMusculoskeletal and connective tissue disorders1/543/563/551/203/163/180/322/351/34
AnaemiaBlood and lymphatic system disorders4/544/562/553/201/160/180/321/353/34
NasopharyngitisInfections and infestations2/542/562/550/202/162/181/321/350/34
HypophosphataemiaMetabolism and nutrition disorders0/541/560/550/202/160/181/320/350/34
HeadacheNervous system disorders2/544/561/550/202/161/181/320/350/34
CoughRespiratory, thoracic and mediastinal disorders1/543/561/550/202/160/181/320/350/34
AcneSkin and subcutaneous tissue disorders0/541/560/550/202/160/180/320/350/34
Muscle spasmsMusculoskeletal and connective tissue disorders0/541/562/550/201/162/181/320/350/34
DizzinessNervous system disorders0/541/561/550/201/162/180/320/350/34

Baseline characteristics

Safety Analysis Set included all participants who received at least 1 dose of study drug in the Blinded Induction Phase.

Age, Continuous
Age, Continuous(years)Andecaliximab Every 2 WeeksAndecaliximab WeeklyPlaceboTotal
Mean44 ± 14.143 ± 13.243 ± 12.843 ± 13.3
Sex: Female, Male
Sex: Female, Male(Participants)Andecaliximab Every 2 WeeksAndecaliximab WeeklyPlaceboTotal
Female19182461
Male353831104
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Andecaliximab Every 2 WeeksAndecaliximab WeeklyPlaceboTotal
Race — White484845141
Race — Black43310
Race — Asian24410
Race — Native Hawaiian or Pacific Islander0011
Race — Not Permitted0011
Race — Other0112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Andecaliximab Every 2 WeeksAndecaliximab WeeklyPlaceboTotal
Ethnicity — Hispanic or Latino0022
Ethnicity — Not Hispanic or Latino545651161
Ethnicity — Not Permitted0022
Region of Enrollment
Region of Enrollment(Participants)Andecaliximab Every 2 WeeksAndecaliximab WeeklyPlaceboTotal
Romania4217
Hungary1225
United States20202161
Czechia1012
Ukraine3339
United Kingdom2226
Switzerland0202
Russia24410
New Zealand0314
Canada0235
South Korea2327
Latvia1001
Netherlands0101
Belgium1326
Ireland0101
Taiwan0101
Poland114823
Italy0224
South Africa1102
Slovakia1001
Australia3025
Bulgaria1001
France0011
08

Study locations

88 sites
  • Dothan, Alabama, United States
  • Wheat Ridge, Colorado, United States
  • Lauderdale Lakes, Florida, United States
  • Miramar, Florida, United States
  • Winter Park, Florida, United States
  • Zephyrhills, Florida, United States
  • Chicago, Illinois, United States
  • Topeka, Kansas, United States
  • Louisville, Kentucky, United States
  • Monroe, Louisiana, United States
  • Ann Arbor, Michigan, United States
  • Plymouth, Minnesota, United States
  • Saint Louis, Missouri, United States
  • Egg Harbor Township, New Jersey, United States
  • New York, New York, United States
  • Chapel Hill, North Carolina, United States
  • Charlotte, North Carolina, United States
  • Mentor, Ohio, United States
  • Rochester, Ohio, United States
  • Germantown, Tennessee, United States
  • Hermitage, Tennessee, United States
  • Arlington, Texas, United States
  • Baytown, Texas, United States
  • Houston, Texas, United States
  • Irving, Texas, United States
  • San Antonio, Texas, United States
  • Southlake, Texas, United States
  • Charlottesville, Virginia, United States
  • Chesapeake, Virginia, United States
  • Norfolk, Virginia, United States
  • Richmond, Virginia, United States
  • Seattle, Washington, United States
  • Wauwatosa, Wisconsin, United States
  • Footscray, Australia
  • Herston, Australia
  • Malvern, Australia
  • Melbourne, Australia
  • Gent, Belgium
  • Leuven, Belgium
  • Mouscron, Belgium
  • Pleven, Bulgaria
  • Victoria, British Columbia, Canada
  • Vaughan, Ontario, Canada
  • Hradec Kralove, Czechia
  • Nantes, France
  • Bekescsaba, Hungary
  • Budapest, Hungary
  • Debrecen, Hungary
  • Dublin, Leinster, Ireland
  • Rozzano, Italy
  • San Giovanni Rotondo, Italy
  • Seoul, Korea, Republic of
  • Suwon-si, Korea, Republic of
  • Daugavpils, Latvia
  • Amsterdam, Netherlands
  • Christchurch, Canterbury Region, New Zealand
  • Auckland, New Zealand
  • Wellington, New Zealand
  • Bialystok, Poland
  • Krakow, Poland
  • Lublin, Poland
  • Piaseczno, Poland
  • Poznan, Poland
  • Sopot, Poland
  • Sroda Wielkopolska, Poland
  • Tychy, Poland
  • Warszawa, Poland
  • Wroclaw, Poland
  • Bucharest, Romania
  • Timisoara, Romania
  • Moscow, Russian Federation
  • Novosibirsk, Russian Federation
  • Rostov-on-Don, Russian Federation
  • Saint-Petersburg, Russian Federation
  • St. Petersburg, Russian Federation
  • Trencin, Slovakia
  • Claremont, Western Cape, South Africa
  • Basel, Switzerland
  • Bern, Switzerland
  • Taichung, Taiwan
  • Kharkov, Ukraine
  • Kyiv, Ukraine
  • Lviv, Ukraine
  • Odessa, Ukraine
  • Vinnitsa, Ukraine
  • Cambridge, United Kingdom
  • Oxford, United Kingdom
  • Prescot, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2015 to primary completion in Sep 2016, 12 months.

Results were first posted in Apr 2019, 2 years 7 months after primary completion. A results delay was requested in Feb 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2015
First posted
Aug 11, 2015
StartActual
Sep 2015
Primary completionActual
Sep 2016
CompletionActual
Nov 2016
Results delay requested
Feb 23, 2017
Results first posted
Apr 10, 2019
Last update
Apr 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02520284
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 11, 2015
Start date
Sep 2015
Primary completion
Sep 2016
Completion
Nov 2016
Results posted
Apr 10, 2019
Last update
Apr 10, 2019

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Andecaliximab

Start the discussion